{"preliminary_commentary":{"by_channel":{"x_thread":29,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02170090\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T08:37:46.950Z","note":"Automated from the 30 newest of 31 indexed sources (May 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":30,"text":"- Whether cisplatin and gemcitabine offer meaningful benefit in the adjuvant setting\n- Whether the findings should change adjuvant treatment practice\n- Which patients, if any, may benefit more from cisplatin and gemcitabine\n- Whether new or biomarker-directed adjuvant strategies are needed\n\nAlso discussed: preserving first-line treatment options."},"drugs_tested":[["gemcitabine","cisplatin"]],"indication":"biliary tract cancer after curative intent resection","name":"ACTICCA-1","nct_id":"NCT02170090","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=acticca-1-nct02170090. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ACTICCA-1","arms":[{"description":"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles)\n\nand Observation","label":"Gemcitabine plus Cisplatin","type":"EXPERIMENTAL"},{"description":"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles)\n\nand Observation","label":"Capecitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":["Deutsche Krebshilfe e.V., Bonn (Germany)","Cancer Research UK","Australasian Gastro-Intestinal Trials Group","Dutch Cancer Society"],"completion_date":{"date":"2025-12","type":"ESTIMATED"},"conditions":["Cholangiocarcinoma","Gall Bladder Carcinoma"],"enrollment":{"count":789,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"}],"last_update":"2025-03-30","lead_sponsor":"Universitätsklinikum Hamburg-Eppendorf","official_title":"Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease free survival (DFS)","timeFrame":"Disease free survival rate at 24 months (DFSR@24)"}],"references":[{"citation":"Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015 Jul 31;15:564. doi: 10.1186/s12885-015-1498-0.","pmid":"26228433","type":"DERIVED"}],"start_date":{"date":"2014-04"},"study_type":"INTERVENTIONAL","title":"Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer","url":"https://clinicaltrials.gov/study/NCT02170090"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/acticca-1-nct02170090"}